Proliferation Determined by Ki-67 Defines Different Pathologic Response to Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer.


BACKGROUND This study aimed to assess the role of proliferation measured by Ki-67 as a predictive factor for pathologic complete response (pCR) to trastuzumab-based chemotherapy in patients with human epidermal growth factor receptor 2 (HER2)-positive (HER2(+)) breast cancer (BC). METHODS A total of 81 patients with HER2(+) BC were treated with a… (More)
DOI: 10.1016/j.clbc.2015.01.005

2 Figures and Tables


  • Presentations referencing similar topics